(CercleFinance.com) – Due to the continued weak general momentum of demand, Sartorius Stedim Biotech announces that it expects its sales to evolve below expectations in the second half of the year and is therefore revising its forecasts for the fiscal year 2023.
On constant exchange rates, the supplier for the pharmaceutical industry now expects revenue to decline by a percentage in the low to mid-tens range, and forecasts a margin of Current EBITDA of around 30%.
The capital expenditure to revenue ratio in 2023 is now estimated at around 15% and the net debt to current EBITDA ratio at around 1.1. Nevertheless, the company does not modify its medium-term objectives until 2025.